Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) EPS (Weighted Average and Diluted) (2021 - 2025)

Lyra Therapeutics has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$3.77 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$3.77 for Q4 2025, up 54.58% from a year ago — trailing twelve months through Dec 2025 was -$12.79 (up 76.52% YoY), and the annual figure for FY2025 was -$18.62, up 74.05%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$3.77 at Lyra Therapeutics, down from -$3.38 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for LYRA hit a ceiling of -$0.13 in Q1 2025 and a floor of -$36.76 in Q2 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.72 (2021), compared with a mean of -$3.7.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 10111.11% in 2024 and later soared 85.01% in 2025.
  • Lyra Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.05 in 2021, then soared by 65.71% to -$0.36 in 2022, then skyrocketed by 38.89% to -$0.22 in 2023, then crashed by 3672.73% to -$8.3 in 2024, then soared by 54.58% to -$3.77 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$3.77 (Q4 2025), -$3.38 (Q3 2025), and -$5.51 (Q2 2025) per Business Quant data.